Bausch Health Companies Inc.: Ulcer trials

The registry lists 14 Ulcer studies with Bausch Health Companies Inc. as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 3 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)CompletedNCT01532648Phase 3Results posted
• The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or ProctosigmoiditisTerminatedNCT01349673Phase 3Results posted
• (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release TabletsCompletedNCT01100112Phase 3Results posted
• Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or ProctosigmoiditisCompletedNCT01008423Phase 3Results posted
• Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or ProctosigmoiditisCompletedNCT01008410Phase 3Results posted
• (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.CompletedNCT00801723Phase 3Results posted
• (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative ColitisCompletedNCT00679432Phase 3Results posted
• (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative ColitisCompletedNCT00679380Phase 3Results posted
• Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis StudyCompletedNCT00486031Phase 3Results posted
• Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in RemissionCompletedNCT00326209Phase 3Results posted
• Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative ColitisCompletedNCT00767728Phase 3
• Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative ColitisCompletedNCT00744016Phase 3
• Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative ColitisCompletedNCT00408174Phase 3
• New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative ColitisCompletedNCT00269438Phase 3